A Cost-Effectiveness Analysis of a Triple-Agent Topical Fixed-Dose Combination of 1.2% Clindamycin Phosphate, 0.15% Adapalene, and 3.1% Benzoyl Peroxide Gel for the Treatment of Moderate-to-Severe Acne Vulgaris in the United States

Speaker(s)

Dey D1, Harper J2, Paul Choudhury S1, Dutta S1, Thomas A1, Bhattacharyya S1, Padula W3, Lin T4, Olujohungbe O5, Jospeh G6, Dashputre A6
1PharmaQuant Insights Pvt. Ltd., Kolkata, WB, India, 2The Dermatology and Skin Care Center of Birmingham, Birmingham, AL, USA, 3University of Southern California, Los Angeles, CA, USA, 4Ortho Dermatologics, Bridgewater, NJ, USA, 5Bausch Health, Somerset, NJ, USA, 6Bausch Health, Bridgewater, NJ, USA

Presentation Documents

OBJECTIVES: Acne is a serious skin condition with significant clinical and economic burden. A novel triple-agent topical fixed-dose combination (FDC) of 1.2% clindamycin phosphate, 0.15% adapalene, and 3.1% benzoyl peroxide gel (BPO) was recently approved by the US FDA for the treatment of acne. This study aimed to evaluate the cost-effectiveness of the triple-agent topical FDC compared to other topical FDCs from the perspective of a commercial payer in the United States.

METHODS: A Markov model with a cycle length of 12 weeks compared costs and quality-adjusted life years (QALYs) of topical FDCs for the treatment of moderate-to-severe acne over a time horizon of 15 years. Efficacy data of the triple-agent FDC were obtained from a pooled analysis of two phase-3 randomized controlled trials. Comparative effectiveness between the triple-agent FDC gel and comparators was estimated using a network meta-analysis of twelve studies. Healthcare resource utilization costs were obtained from a claims database analysis. Other model inputs were sourced from published literature. Costs and QALYs were discounted at 3% annually and compared to a range of willingness-to-pay (WTP) thresholds at $50,000/QALY, $100,000/QALY, and $150,000/QALY.

RESULTS: The wholesale acquisition cost of triple-agent FDC was $950 per 50g pump. Total costs for the triple-agent FDC were $70,206 vs. $64,540 for topical retinoid/BPO FDC. The Effectiveness of triple-agent FDC was 10.42 QALYs vs. 10.25 QALYs for topical retinoid/BPO FDC. At an incremental cost of $5,665 and incremental effectiveness of 0.17 QALYs, the resulting incremental cost-effectiveness ratio of $32,764/QALY implies triple-agent FDC is cost-effective at any threshold. The cost of triple agent FDC was ~31%, ~63%, and ~75% below the threshold for the stated range of WTP thresholds.

CONCLUSIONS: Our findings suggest that the triple-agent topical FDC gel could be a cost-effective treatment for patients with moderate-to-severe acne from the perspective of a commercial payer in the US.

Code

EE404

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Drugs, Sensory System Disorders (Ear, Eye, Dental, Skin)